DYN
Dyne Therapeutics, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Neutral
-8/100
Last price
15.91
▲ 0.51 (3.34%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
15.50
Prev close
15.40
Day high
15.99
Day low
15.25
Volume
671.90K
Market cap
$2.97B
P/E (TTM)
—
52W range
13.73 – 27.31
Day trading desk
Gap from prior close
+0.65%
Prior close 15.40
VWAP
15.72
+1.26% from price
Relative volume
0.24×
Quiet session
Session range
4.85%
15.24 – 15.98
Position in range
91%
Near session high
ATR (14D)
0.77
4.87% of price
Prior day high
15.59
PDH
Prior day low
14.93
PDL
Bid / ask spread
—
Quote not published
Session volume
670.38K
Avg 2.76M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-1.21%
-2.8%
1M
-21.64%
-22.8%
3M
-34.43%
-37.5%
6M
-13.41%
-28.0%
YTD
-18.63%
-32.2%
1Y
+25.81%
+10.5%
3Y
+100.44%
+19.2%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on DYN open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
-6.72M
Net selling
Buy transactions
6
65.13K shares
Sell transactions
29
6.78M shares
Net transactions
+35
Buys less sells
Sell : buy shares
104.1 : 1
Heavily one-sided
Insider-held shares
438.85K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Oct 2, 26 | POSNER BRIAN S. Director |
BUY | 2.50K | $40.00K | Direct |
| Sep 8, 26 | KERR DOUGLAS Officer |
SELL | 5.04K | $115.55K | Direct |
| Sep 8, 26 | COX JOHN Chief Executive Officer |
SELL | 5.66K | $106.82K | Direct |
| Sep 8, 26 | FRIEDL-NADERER JOHANNA Officer |
SELL | 1.08K | $26.41K | Direct |
| Aug 14, 26 | RHODES JASON P Director |
SELL | 2.59M | $65.18M | Indirect |
| Aug 13, 26 | LUCERA ERICK J. Chief Financial Officer |
SELL | 1.80K | $47.23K | Direct |
| Aug 13, 26 | KERR DOUGLAS Officer |
SELL | 1.56K | $40.89K | Direct |
| Aug 13, 26 | COX JOHN Chief Executive Officer |
SELL | 4.99K | $131.03K | Direct |
| Aug 13, 26 | FRIEDL-NADERER JOHANNA Officer |
SELL | 226 | $5.94K | Direct |
| Jul 27, 26 | KERSTEN DIRK Director |
SELL | 261.46K | $6.67M | Indirect |
| Jul 7, 26 | RHODES JASON P Director |
SELL | 777.45K | $17.86M | Indirect |
| Jun 29, 26 | RHODES JASON P Director |
SELL | 504.69K | $10.71M | Indirect |
| Jun 25, 26 | RHODES JASON P Director |
SELL | 267.76K | $5.65M | Indirect |
| Jun 25, 26 | LUCERA ERICK J. Chief Financial Officer |
SELL | 2.36K | $48.11K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BESKROVNAYA OXANA |
Officer | 195.84K | Sale |
COX JOHN |
Chief Executive Officer | 429.51K | Sale |
FRIEDL-NADERER JOHANNA |
Officer | 152.90K | Sale |
KERR DOUGLAS |
Officer | 162.56K | Sale |
KERSTEN DIRK |
Director | — | Sale |
LUBNER DAVID CHARLES |
Director | 0 | Stock Gift |
LUCERA ERICK J. |
Chief Financial Officer | 119.77K | Sale |
POSNER BRIAN S. |
Director | 27.00K | Purchase |
RHODES JASON P |
Director | — | Sale |
SCALZO RICHARD WILLIAM |
Officer | 122.33K | Sale |
Fundamentals
Market cap$2.97B
Enterprise value$2.21B
Revenue (TTM)—
Gross profit—
EBITDA$-534.80M
Net income$-519.40M
EPS (TTM)$-3.30
Free cash flow$-317.14M
Total cash$898.48M
Total debt$233.35M
Book value / share$4.24
Shares outstanding186.75M
Float186.24M
Short % of float16.01%
Dividend yield0.00%
Beta (5Y)1.12
Valuation & profitability ratios
Trailing P/E—
Forward P/E-4.77
PEG ratio—
Price / sales—
Price / book3.76
EV / revenue—
EV / EBITDA-4.13
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-81.57%
Return on assets-38.96%
Debt / equity33.23
Current ratio12.02
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $398.33M | $281.41M | $210.76M | $142.76M | +41.6% |
| Selling, general & admin | $69.85M | $62.48M | $31.40M | $28.20M | +11.8% |
| Total operating expense | $468.18M | $343.89M | $242.16M | $170.96M | +36.1% |
| Operating income | -$468.18M | -$343.89M | -$242.16M | -$170.96M | -36.1% |
| Net interest income | $23.67M | $26.92M | $7.64M | $2.92M | -12.1% |
| Pre-tax income | -$446.21M | -$317.42M | -$235.94M | -$168.10M | -40.6% |
| Net income | -$446.21M | -$317.42M | -$235.94M | -$168.10M | -40.6% |
| Net income to common | -$446.21M | -$317.42M | -$235.94M | -$168.10M | -40.6% |
| Basic EPS | -3.47 | -3.37 | -3.95 | -3.23 | -3.0% |
| Diluted EPS | -3.47 | -3.37 | -3.95 | -3.23 | -3.0% |
| EBIT | -$440.02M | -$317.42M | -$235.94M | -$170.96M | -38.6% |
| EBITDA | -$437.97M | -$315.75M | -$234.26M | -$169.28M | -38.7% |
| Basic shares | 128.44M | 94.14M | 59.68M | 51.98M | +36.4% |
| Diluted shares | 128.44M | 94.14M | 59.68M | 51.98M | +36.4% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $893.37M | $435.45M | $121.63M | $172.15M | +105.2% |
| Cash & short-term investments | $1.11B | $642.27M | $123.10M | $256.01M | +72.9% |
| Total current assets | $1.13B | $659.28M | $129.38M | $265.59M | +70.9% |
| Property, plant & equipment | $44.77M | $30.01M | $33.39M | $38.41M | +49.2% |
| Total assets | $1.19B | $691.23M | $165.08M | $306.32M | +71.7% |
| Total current liabilities | $50.63M | $42.26M | $51.09M | $28.09M | +19.8% |
| Long-term debt | $148.92M | — | — | — | — |
| Total debt | $169.20M | $23.99M | $27.41M | $30.48M | +605.3% |
| Total liabilities | $214.83M | $61.40M | $73.79M | $53.96M | +249.9% |
| Retained earnings | -$1.40B | -$949.93M | -$632.51M | -$396.57M | -47.0% |
| Shareholder equity | $972.13M | $629.84M | $91.29M | $252.36M | +54.3% |
| Working capital | $1.08B | $617.02M | $78.28M | $237.51M | +74.4% |
| Net tangible assets | $972.13M | $629.84M | $91.29M | $252.36M | +54.3% |
| Shares issued | 164.95M | 102.32M | 61.47M | 55.64M | +61.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$446.21M | -$317.42M | -$235.94M | -$168.10M | -40.6% |
| Depreciation & amortisation | $2.05M | $1.67M | $1.67M | $1.68M | +22.5% |
| Stock-based compensation | $45.85M | $45.86M | $19.97M | $15.18M | -0.0% |
| Change in working capital | -$3.40M | -$19.49M | $26.31M | -$5.38M | +82.5% |
| Operating cash flow | -$403.21M | -$292.37M | -$188.16M | -$153.65M | -37.9% |
| Capital expenditure | -$20.71M | -$2.38M | -$729.00K | -$3.07M | -771.6% |
| Investing cash flow | -$28.75M | -$204.08M | $83.31M | $87.20M | +85.9% |
| Financing cash flow | $890.31M | $809.89M | $54.32M | $37.39M | +9.9% |
| Free cash flow | -$423.92M | -$294.75M | -$188.89M | -$156.71M | -43.8% |
| End cash position | $895.74M | $437.39M | $123.94M | $174.47M | +104.8% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — |
| Research & development | $152.17M | $100.89M | $95.43M | $97.22M | $99.24M | +50.8% |
| Selling, general & admin | $29.49M | $24.39M | $20.70M | $16.67M | $16.55M | +20.9% |
| Total operating expense | $181.66M | $125.28M | $116.13M | $113.89M | $115.79M | +45.0% |
| Operating income | -$181.66M | -$125.28M | -$116.13M | -$113.89M | -$115.79M | -45.0% |
| Net interest income | $3.19M | $4.55M | $4.46M | $5.57M | $6.53M | -29.9% |
| Pre-tax income | -$178.56M | -$120.85M | -$111.95M | -$108.04M | -$110.86M | -47.7% |
| Net income | -$178.56M | -$120.85M | -$111.95M | -$108.04M | -$110.86M | -47.7% |
| Net income to common | -$178.56M | -$120.85M | -$111.95M | -$108.04M | -$110.86M | -47.7% |
| Basic EPS | -1.08 | -0.73 | -0.76 | -0.76 | -0.97 | -47.9% |
| Diluted EPS | -1.08 | -0.73 | -0.76 | -0.76 | -0.97 | -47.9% |
| EBIT | -$173.96M | -$116.65M | -$108.76M | -$105.14M | -$110.76M | -49.1% |
| EBITDA | -$173.40M | -$116.10M | -$108.24M | -$104.61M | -$110.26M | -49.4% |
| Basic shares | 165.45M | 165.04M | 147.62M | 141.81M | 113.87M | +0.3% |
| Diluted shares | 165.45M | 165.04M | 147.62M | 141.81M | 113.87M | +0.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $676.11M | $753.10M | $893.37M | $573.61M | $485.04M | -10.2% |
| Cash & short-term investments | $898.48M | $972.16M | $1.11B | $791.89M | $683.92M | -7.6% |
| Total current assets | $937.89M | $1.02B | $1.13B | $806.26M | $697.95M | -8.1% |
| Property, plant & equipment | $44.81M | $43.33M | $44.77M | $45.79M | $28.53M | +3.4% |
| Total assets | $994.01M | $1.08B | $1.19B | $867.06M | $728.99M | -8.0% |
| Total current liabilities | $78.03M | $51.25M | $50.63M | $59.85M | $41.47M | +52.3% |
| Long-term debt | $199.33M | $149.38M | $148.92M | $99.15M | $98.81M | +33.4% |
| Total debt | $219.20M | $168.68M | $169.20M | $120.47M | $121.08M | +30.0% |
| Total liabilities | $291.86M | $214.90M | $214.83M | $175.28M | $157.55M | +35.8% |
| Retained earnings | -$1.70B | -$1.52B | -$1.40B | -$1.28B | -$1.18B | -11.8% |
| Shareholder equity | $702.15M | $865.05M | $972.13M | $691.78M | $571.45M | -18.8% |
| Working capital | $859.86M | $969.78M | $1.08B | $746.41M | $656.48M | -11.3% |
| Net tangible assets | $702.15M | $865.05M | $972.13M | $691.78M | $571.45M | -18.8% |
| Shares issued | 165.67M | 165.20M | 164.95M | 142.61M | 114.34M | +0.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$178.56M | -$120.85M | -$111.95M | -$108.04M | -$110.86M | — | -47.7% |
| Depreciation & amortisation | $560.00K | $550.00K | $521.00K | $523.00K | $503.00K | — | +1.8% |
| Stock-based compensation | $14.98M | $13.08M | $11.23M | $11.08M | $10.52M | — | +14.5% |
| Change in working capital | $32.80M | -$37.62M | -$11.31M | $5.87M | $5.64M | — | +187.2% |
| Operating cash flow | -$130.29M | -$144.92M | -$111.83M | -$90.78M | -$94.70M | — | +10.1% |
| Capital expenditure | -$1.51M | -$221.00K | -$484.00K | -$19.18M | -$60.00K | — | -585.1% |
| Investing cash flow | -$4.79M | -$2.39M | $982.00K | -$37.97M | $6.77M | — | -100.5% |
| Financing cash flow | $58.11M | $7.06M | $430.96M | $217.33M | $100.77M | — | +722.6% |
| Free cash flow | -$131.80M | -$145.14M | -$112.32M | -$109.96M | -$94.76M | — | +9.2% |
| End cash position | — | — | $895.74M | $575.63M | $487.04M | $474.20M | — |
Options analytics
Put / call volume
3.17
Put-heavy session
Put / call open interest
0.32
Positioning, not flow
Max pain
17.50
+10.0% from spot
ATM implied vol
68.6%
Nearest strike to spot
Skew (10% OTM)
-17.6%
Calls bid over puts
Call volume
76
Contracts, this expiry
Put volume
241
Contracts, this expiry
Heaviest call OI
22.50
764 contracts
Heaviest put OI
15.00
314 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.75 | -1.08 | -44.3% |
| Mar 2026 | -0.78 | -0.73 | +6.7% |
| Dec 2025 | -0.76 | -0.73 | +4.4% |
| Sep 2025 | -0.85 | -0.76 | +10.1% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.89 | 14 | $0 | 0.0% |
| Next quarter | -0.89 | 14 | $0 | 0.0% |
| Current year | -3.55 | 15 | $0 | 0.0% |
| Next year | -3.34 | 13 | $52.80M | 0.0% |
Analyst targets & ownership
Mean target$36.00
High target$50.00
Low target$10.00
Implied upside126.20%
Analyst count15
ConsensusSTRONG BUY
Strong buy / Buy3 / 13
Hold0
Sell / Strong sell0 / 1
Held by insiders0.24%
Held by institutions103.69%
Institutions holding334
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
15.90
+0.11% from price
SMA 20
16.75
-4.98% from price
SMA 50
21.94
-27.45% from price
SMA 100
21.24
-25.09% from price
SMA 200
19.56
-18.64% from price
EMA 12
16.29
-2.28% from price
EMA 26
18.10
-12.08% from price
EMA 50
19.88
-19.96% from price
RSI (14)
30.0
Oversold
MACD (12,26,9)
-1.82
Hist 0.15
ATR (14)
0.77
4.87% of price
Realised vol 30D
62.5%
Annualised
Bollinger upper
18.80
20, 2σ
Bollinger lower
14.70
20, 2σ
50 / 200 cross
Golden
21.94 vs 19.56
Trend bias
Below 200
-18.64%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
2.03
More volatile than market
Correlation to SPY
0.34
Loosely linked
Realised vol 30D
62.5%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-43.2%
Peak to trough
Max drawdown 5Y
-85.5%
Peak to trough
ATR 14
0.77
4.87% of price
Beta (reported)
1.12
5Y monthly, from filing
Short interest
Shares short
23.38M
Prior 21.46M
Change vs prior
+9.0%
Shorts adding
% of float
16.01%
Elevated
% of shares out
12.52%
Against total outstanding
Days to cover
8.0
Crowded exit
Float
186.24M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 30, 26 | Chardan Capital | MAINTAINED | Buy | Buy |
| Sep 30, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Sep 29, 26 | Piper Sandler | MAINTAINED | Overweight | Overweight |
| Sep 9, 26 | Morgan Stanley | MAINTAINED | Overweight | Overweight |
| Sep 9, 26 | JP Morgan | DOWNGRADE | Neutral | Underweight |
| Sep 9, 26 | RBC Capital | MAINTAINED | Outperform | Outperform |
| Sep 9, 26 | Baird | MAINTAINED | Outperform | Outperform |
| Jul 31, 26 | Morgan Stanley | MAINTAINED | Overweight | Overweight |
| Jul 30, 26 | RBC Capital | MAINTAINED | Outperform | Outperform |
| Jul 23, 26 | Cantor Fitzgerald | INITIATED | — | Overweight |
| Jun 26, 26 | TD Cowen | INITIATED | — | Buy |
| May 15, 26 | Evercore ISI Group | MAINTAINED | Outperform | Outperform |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-29
Periodic Financial Reports
10-Q · 2026-07-29
Corporate Changes & Voting Matters
8-K · 2026-07-22
Corporate Changes & Voting Matters
8-K · 2026-07-20
Corporate Changes & Voting Matters
8-K · 2026-06-22
Corporate Changes & Voting Matters
8-K · 2026-06-17
Corporate Changes & Voting Matters
8-K · 2026-06-08
Corporate Changes & Voting Matters
8-K · 2026-06-03
Headlines
Why Dyne Therapeutics (DYN) Is Back In The Spotlight
Simply Wall St. · 2h ago
Dyne Therapeutics stock rises on positive DM1 trial results
Investing.com · 8d ago
Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)
GlobeNewswire · 8d ago
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · 20d ago
Do Dyne Therapeutics’ (DYN) Expanded DM1 Data Presentations Redefine Its Rare-Disease Investment Narrative?
Simply Wall St. · 20d ago
Wall Street Weighs Impact On DYN Stock Post Novartis’ Phase 3 Failure — RBC Says These Key Differences Could Lead To Better Outcomes
Stocktwits · 28d ago
Dyne Therapeutics Myotonic Dystrophy Approach Remains Differentiated, RBC Says
MT Newswires · 28d ago
Uber initiated, Thermo Fisher upgraded: Wall Street's top analyst calls
The Fly · 28d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.